Amgen buys Horizon Therapeutics for $27B
By Jorge Mercado Senior Staff Writer Thousand Oaks-based Amgen has announced its largest acquisition in company history, $27 billion for Horizon Therapeutics, positioning itself with a pipeline of treatments that could pay dividends over the coming decades. Amgen, one of the largest biotechnology companies in the world, beat out competition from Sanofi and Johnson and Read More →
Dantari raises $47M to target cancers and rare diseases
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
The sound of going green
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
<strong>Failure to report</strong>
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen buys Horizon Therapeutics for $27B in cash
Thousand Oaks-based Amgen today announced its largest acquisition in company history, $27 billion for Horizon Therapeutics, positioning itself with a pipeline of treatments that could pay dividends over the coming decades. Amgen, one of the largest biotechnology companies in the world, beat out competition from Sanofi and Johnson and Johnson, both of whom bowed out Read More →
Despite critics, Amgen sticks to its game plan
During its 42 years as a biotech company based in Thousand Oaks, Amgen has fiercely protected its independence, while rising to the top ranks of pharma companies, often by acquiring companies with drugs. The blockbuster transaction announced on Dec. 12 to acquire Horizon Therapeutics fits that growth pattern and it matches up with the company’s Read More →
Semtech earnings are down, despite outdistancing third quarter estimates
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
